/
Oncology
Differentiated Thyroid Carcinoma
12
Pipeline Programs↗
8
Active Trials↗
7
Companies Involved↗
Differentiated Thyroid Carcinoma is an emerging landscape with 12 programs across 7 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 24
Phase 34
Approved
No programs
Analysis
Trial Status
15
clinical trials
Unknown status6 · 40%
Recruiting4 · 27%
Not yet recruiting2 · 13%
Active, not recruiting2 · 13%
Completed1 · 7%
Clinical Trials
Trial Activity
15 trials
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Recruiting·—·Phase 2·NCT06440850·21 enrolled
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
Active, not recruiting·—·Phase 2·NCT05007093·20 enrolled
Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma
Unknown status·TThe Affiliated Hospital of Inner Mongolia Medical University·N/A·NCT02665325·100 enrolled
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03167385·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)